Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingGeoffrey Y. Ku, Jedd D. Wolchok, Jianda Yuan et al.|Cancer|2010Cited by 422
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Geoffrey Y. Ku, Yelena Y. Janjigian et al.|The Lancet Oncology|2023Cited by 237
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73
RETRACTED: Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumorsYelena Y. Janjigian, Luis A. Díaz, Melissa Lumish et al.|Research Square|2025Cited by 0